Drug Shortage Report for TRAVASOL

Last updated on 2021-10-02 History
Report ID 145280
Drug Identification Number 00872296
Brand name TRAVASOL
Common or Proper name TRAVASOL Amino acids (Blend C) injection
Company Name BAXTER CORPORATION
Market Status MARKETED
Active Ingredient(s) LEUCINE SERINE TYROSINE PROLINE ARGININE GLYCINE L-ALANINE TRYPTOPHAN THREONINE HISTIDINE VALINE ISOLEUCINE L-LYSINE METHIONINE PHENYLALANINE
Strength(s) 730MG 500MG 40MG 680MG 1.15G 1.03G 2.07G 180MG 420MG 480MG 580MG 600MG 580MG 400MG 560MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 3000 mL (JB6583)
ATC code B05BA
ATC description I.V. SOLUTIONS
Reason for shortage Shortage of an active ingredient.
Anticipated start date 2021-09-07
Actual start date 2021-09-07
Estimated end date
Actual end date 2021-10-01
Shortage status Resolved
Updated date 2021-10-02
Company comments Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order.
Health Canada comments
Contact Address 7125 MISSISSAUGA ROAD
MISSISSAUGA, ONTARIO
CANADA L5N 0C2
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v6 2021-10-02 English Compare
v5 2021-10-01 French Compare
v4 2021-10-01 English Compare
v3 2021-09-08 English Compare
v2 2021-09-07 French Compare
v1 2021-09-07 English Compare